Infancy represents the period in which an individual may be at the highest risk of sensitization. During the first year of life around 2.5% of neonates experience hypersensitivity reactions to cow's milk protein, which is highly associated with early exposure to cow's milk. Attempts to avoid sensitization in this very early period of life and to prevent allergic diseases focus on diets with reduced allergenicity and possibly on the induction of oral tolerance. Hydrolyzed infant formulas are characterized by a reduced allergenicity and thus recommended as substitute or supplementary to breastfeeding during the first 4-6 months of life for infants at high risk of developing atopic diseases. This concept of hypoallergenicity has been shown effective in clinical studies. Both partially and extensively hydrolyzed formulas have demonstrated a potential in protecting from allergic diseases, mainly atopic eczema and food allergy. The in vitro characterization of allergenicity by the degree of hydrolyzation and peptide size, however, does not necessarily predict the immunogenic effect in humans, as it could be shown that the preventive effect seems to be dependent on the process rather than on the degree of hydrolyzation, which could be best explained by a possible production of tolerogenic epitopes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000098512 | DOI Listing |
Food Chem
January 2025
Technological Institute of Food and Agriculture (INTAEX), Centro de Investigaciones Científicas y Tecnológicas de Extremadura (CICYTEX). Avda. Adolfo Suárez s/n, 06007, Badajoz, Spain.
Cow's milk allergy caused by a hypersensitivity to milk proteins has increased over the last years. Hypoallergenic responses can be induced by altering the structure of such proteins with chemical modifiers; this paper is about the creation of edible matrices based on polyphenols from orange peel. Some compounds were able to significantly lower the IgE binding from β-lactoglobulin allergic serum in sensitized patients.
View Article and Find Full Text PDFANZ J Surg
November 2024
Discipline of Medical Specialties, University of Adelaide, Adelaide, South Australia, Australia.
Introduction: Clinical recognition of potential immune-mediated allergic responses to implanted metal devices is increasing. For orthopaedic implants, while 'pure' compounds are used in specific circumstances, the majority of components are alloys - a combination of two or more distinct metals. Titanium is found commonly in many orthopaedic devices and is often championed as a 'hypoallergenic' option or inclusion.
View Article and Find Full Text PDFJ Allergy Clin Immunol Pract
January 2020
Department of Allergy and Immunology, Royal Children's Hospital, Melbourne, VIC, Australia.
Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE-mediated food allergy that manifests with projectile, repetitive emesis that can be followed by diarrhea and may be accompanied by lethargy, hypotonia, hypothermia, hypotension, and metabolic derangements. FPIES usually starts in infancy although onset at older ages is being increasingly recognized. FPIES is not rare, with the cumulative incidence of FPIES in infants estimated to be 0.
View Article and Find Full Text PDFAllergo J Int
May 2018
1Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, 28040 Madrid, Spain.
Allergen-specific immunotherapy (AIT) is the single disease-modifying treatment for allergy. Clinical trials show AIT to be safe and effective for many patients; however, it still faces problems related to efficacy, safety, long treatment duration and low patient adherence. There has been intensive research to develop alternative strategies, including novel administration routes, adjuvants or hypoallergenic molecules.
View Article and Find Full Text PDFJ Allergy Clin Immunol
November 2017
Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland. Electronic address:
Allergen immunotherapy (AIT) is an effective treatment strategy for allergic diseases and has been used for more than 100 years. In recent years, however, the expectations on concepts, conduct, statistical evaluation, and reporting have developed significantly. Products have undergone dose-response and confirmative studies in adults and children to provide evidence for the optimal dosage, safety, and efficacy of AIT vaccines using subcutaneous and sublingual delivery pathways in large patient cohorts, ensuring solid conclusions to be drawn from them for the advantage of patients and societies alike.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!